Abstracts Archive - Page 1260 of 2425 - ACR Meeting Abstracts

Abstract Number: 817 • 2017 ACR/ARHP Annual Meeting
Extension of Affected Vascular Territories in Secondary Aortitis Is Associated to Different Clinical Subtypes?
Nuria Vegas-Revenga¹, Javier Loricera¹, Diana Prieto Peña¹, Isabel Martínez-Rodríguez¹, Jose Ignacio Banzo², Monica Calderón Goercke³, Jesus Gonzalez- Vela¹, Jose L. Hernández¹, Vanesa Calvo-Río¹, Lucia C. Domínguez-Casas¹, José Luis Martín-Varillas³, Belén Atienza-Mateo³, MC Gonzalez-Vela¹, Miguel Angel González-Gay¹ and Ricardo Blanco³, ¹Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ²Nuclear Medicine, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ³Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain
Background/Purpose: Aortitis is characterized by inflammation of the aortic wall. Aortitis may be associated with different conditions. Our aim was to assess if the different…
Abstract Number: 818 • 2017 ACR/ARHP Annual Meeting
Correlation between the Routine Assessment of Patient Index Data (RAPID3) and Inflammatory Markers in Patients with PMR
Tiffany Kolniak¹, Joshua Baker², Abhijeet Danve³ and Shiv Tej Sehra⁴, ¹Internal Medicine, Mount Auburn Hospital, Harvard Medical School, Cambridge, MA, ²Rheumatology, University of Pennsylvania, Philadelphia, PA, ³Yale University, New Haven, CT, ⁴Rheumatology, Mount Auburn Hospital, Harvard Medical School, Cambridge, MA
Background/Purpose: The routine assessment of patient index data (RAPID3) was developed for monitoring and prognosis of patients with Rheumatoid Arthritis and has since been extended…
Abstract Number: 819 • 2017 ACR/ARHP Annual Meeting
Risks of Non-Cardiovascular Corticosteroid Related Adverse Events and Cancer in Giant Cell Arteritis: A French Population-Based Cohort Study
Minh Phuong Do¹, Grégory Pugnet², Guillaume Moulis³, Gregory Guernec⁴, Maryse Lapeyre-Mestre⁵ and Laurent Sailler⁶, ¹Faculté de Médecine, Toulouse University, Laboratoire de Pharmacoepidemiologie, Equipe émergente,UMR INSERM 1027, Toulouse, France, ²Department of Internal Medicine, Toulouse University Hospital, University of Toulouse, INSERM UMR 1027, Toulouse, France, ³Internal Medicine, Toulouse University Hospital, Toulouse, France, ⁴Faculté de Médecine, Toulouse University, UMR INSERM 1027, Toulouse, France, ⁵UMR 1027, INSERM-University of Toulouse, Toulouse, France, ⁶Medecine Interne, CHU Toulouse, Toulouse, France
Background/Purpose: Corticosteroid related adverse events are a main concern in patients suffering from giant cell arteritis. Conflicting results are reported on this topic, recurrent events…
Abstract Number: 820 • 2017 ACR/ARHP Annual Meeting
Prognostic Value of Positron Emission Tomography in a Prospective, Longitudinal Cohort of Patients with Large Vessel Vasculitis
Peter C. Grayson¹, Sara Alehashemi², Armin Bagheri³, Ali Cahid Civelek⁴, Thomas Cupps⁵, Mariana J. Kaplan⁶, Ashkan Malayeri⁴, Peter A. Merkel⁷, Elaine Novakovich⁸, David A. Bluemke⁴ and Mark Ahlman⁴, ¹National Institute of Arthritis, Musculoskeletal and Skin Disease (NIAMS), Bethesda, MD, ²Rheumatology, National Institutes of Health, Bethesda, MD, ³Vasculitis Translational Research Program, NIAMS, NIH, Bethesda, MD, ⁴Radiology and Imaging Sciences, National Institutes of Health, Bethesda, MD, ⁵Rheumatology, Georgetown University, Bethesda, MD, ⁶NIAMS/NIH, Bethesda, MD, ⁷University of Pennsylvania, Philadelphia, MN, ⁸Systemic Autoimmunity Branch, NIAMS, National Institutes of Health, Bethesda, MD
Background/Purpose: While several studies have examined the potential of 18F-flurodeoxyglucose (FDG) positron emission tomography (PET) to help establish a diagnosis of large vessel vasculitis (LVV),…
Abstract Number: 821 • 2017 ACR/ARHP Annual Meeting
Discrepancies between Clinical- and Imaging-Based Assessments of Disease Activity in Takayasu’s Arteritis
Peter C. Grayson¹, Mark Ahlman², Kathleen Marinelli³, Renee Borchin⁴, Simon Carette⁵, Nader A. Khalidi⁶, Carol A. Langford⁷, Carol A. McAlear⁸, Paul A. Monach⁹, Christian Pagnoux⁵, Kenneth J. Warrington¹⁰, Steven R. Ytterberg¹⁰ and Peter A. Merkel¹¹, ¹National Institute of Arthritis, Musculoskeletal and Skin Disease (NIAMS), Bethesda, MD, ²Radiology and Imaging Sciences, National Institutes of Health, Bethesda, MD, ³NIAMS, National Institutes of Health, Bethesda, MD, ⁴University of South Florida, Tampa, FL, ⁵Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁶Rheumatology, McMaster University, Hamilton, ON, Canada, ⁷Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ⁸University of Pennsylvania, Philadelphia, PA, ⁹Boston University School of Medicine, Boston, MA, ¹⁰Rheumatology, Mayo Clinic, Rochester, MN, ¹¹Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, PA
Background/Purpose: To study the relationship between clinically-determined disease activity and vascular inflammation assessed by positron emission tomography (PET) in patients with TakayasuÕs arteritis (TAK). Methods:…
Abstract Number: 822 • 2017 ACR/ARHP Annual Meeting
The Incidence Rate of Deep Vein Thrombosis and/or Pulmonary Embolism in Patients with Giant Cell Arteritis – Single Center Observational Study
Rok Jese¹, Alenka Mavri², Ziga Rotar¹, Natasa Kejzar³, Sonja Praprotnik¹, Matija Tomsic¹ and Alojzija Hočevar¹, ¹Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, ²University Medical Centre Ljubljana, Ljubljana, Slovenia, ³Faculty of Medicine, Institute for Biostatistics and Medical Informatics, University of Ljubljana, Ljubljana, Slovenia
Background/Purpose: Recent studies have indicated a higher incidence of deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients with giant cell arteritis (GCA)1,2. Our…
Abstract Number: 823 • 2017 ACR/ARHP Annual Meeting
Seasonal Variation in Giant Cell Arteritis and Polymyalgia Rheumatica Hospitalizations: Data from Nationwide Inpatient Sample
Paras Karmacharya¹, Dilli Poudel², Pragya Shrestha³, Rashmi Dhital⁴ and Raju Khanal⁴, ¹Division of Rheumatology, Mayo Clinic, Rochester, MN, ²Internal Medicine, Reading Health System, WEST READING, PA, ³Internal medicine, Reading Health System, West Reading, PA, ⁴Internal Medicine, Reading Health System, West Reading, PA
Background/Purpose: Most studies looking at seasonal variations in giant cell arteritis (GCA) note a seasonal trend, but show disparity on timing. Concurrent peaks of GCA…
Abstract Number: 824 • 2017 ACR/ARHP Annual Meeting
Long Term Efficacy and Safety of Intravenous and Subcutaneous Biologics in Large Vessels Vasculitis: 21 Patients Belonging to a Single Italian Center from 2011 to 2017
Paola Toniati¹ and Angela Tincani², ¹RHEUMATOLOGY, SPEDALI CIVILI, BRESCIA, Italy, ²University and Spedali Civili of Brescia, Brescia, Italy
Background/Purpose: Large vessels vasculitis (LVV) is the most common form of primary vasculitis comprising giant cell arteritis (GCA) and Takayasu arteritis (TAK) and aortitis. Methods:…
Abstract Number: 825 • 2017 ACR/ARHP Annual Meeting
Radiological Disease Activity Is the Major Determinant for Physicians While Deciding Active Disease in Takayasu Arteritis
Gokce Kenar¹, Sedanur Karaman², Pinar Cetin³, Handan Yarkan⁴, Berrin Zengin¹, Gercek Can¹, Merih Birlik⁵ and Fatos Onen¹, ¹Rheumatology, Dokuz Eylul University Faculty of Medicine, Izmir, Turkey, ²Internal Medicine, Dokuz Eylul Universty, izmir, Turkey, ³Rheumatology, Dumlupınar University School of Medicine, Kutahya, Turkey, ⁴Rheumatology, Dokuz Eylul University Faculty of Medicine, İzmir, Turkey, ⁵Rheumatology, Dokuz Eylul University Faculty of Medicine, izmir, Turkey
Background/Purpose:There are no valid followup parameters in the assessment of disease activity in Takayasu arteritis(TA).We investigated the impact of incorporation of vascular imaging into ITAS…
Abstract Number: 826 • 2017 ACR/ARHP Annual Meeting
TGF-β-Induced Epigenetic Silencing of SOCS3 Facilitates STAT3 Signaling to Promote Fibroblast Activation and Tissue Fibrosis in Systemic Sclerosis
Clara Dees¹, Yun Zhang², Sebastian Poetter¹, Christina Bergmann³, Andreas Ramming⁴, Oliver Distler⁵, Georg Schett⁶ and Jörg Distler⁷, ¹Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ²Department of Internal Medicine 3 and Institute for Clinical Immunology, Department of Internal Medicine 3 and Institute for Clinical Immunology, Friedrich-Alexander-University of Erlangen-Nuremberg and University Hospital Erlangen, Erlangen, Germany, ³Department of Internal Medicine 3 and Institute for Clinical Immunology, Friedrich-Alexander-University of Erlangen-Nuremberg and University Hospital Erlangen, Erlangen, Germany, ⁴Department of Internal Medicine 3 – Rheumatology and Immunology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, ⁵Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ⁶Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Department of Internal Medicine 3 – Rheumatology and Immunology, Universitätsklinikum Erlangen, Erlangen, Germany., Erlangen, Germany, ⁷Department of Internal Medicine 3 – Rheumatology and Immunology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany
Background/Purpose: Tissue fibrosis caused by pathological activation of fibroblasts is a major hallmark of systemic sclerosis (SSc). Although fibroblast activation is initially driven by external…
Abstract Number: 827 • 2017 ACR/ARHP Annual Meeting
Temporary Methotrexate Discontinuation for 2 Weeks Improves Immunogenicity of Seasonal Influenza Vaccination in Patients with Rheumatoid Arthritis: A Randomized Clinical Trial
Jin Kyun Park¹, Kichul Shin², You-Jung Ha³, Yun Jong Lee⁴, Eun Young Lee⁵, Yeong Wook Song⁶, Yunhee Choi⁷, Kevin Winthrop⁸ and Eun Bong Lee⁹, ¹Division of Rheumatology, Seoul National University Hospital, Seoul, Korea, Republic of (South), ²Kyungnam villa #102, Division of Rheumatology, Department of Internal Medicine, SMG-SNU Boramae Medical Center, Seoul, Korea, Republic of (South), ³Yonsei University College of Medicine, Seoul, Korea, Republic of (South), ⁴Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea, Republic of (South), ⁵Division of Rheumatology, Department of Internal Medicine, Seoul National University, Seoul, Korea, Republic of (South), ⁶Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, and College of Medicine, Seoul National University, Seoul, Korea, The Republic of, Seoul, Korea, Republic of (South), ⁷Division of Medical Statistics, Medical Research Collaborating Center, Seoul National University College of Medicine, Seoul, Korea, Republic of (South), ⁸Oregon Health & Science University, Portland, OR, ⁹Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Republic of (South)
Background/Purpose: Methotrexate (MTX), a widely used immune-suppressive agent, decreases vaccine response in patients with rheumatoid arthritis (RA). We investigated whether a temporary MTX discontinuation for…
Abstract Number: 828 • 2017 ACR/ARHP Annual Meeting
The Impact of the Duration of Bisphosphonate Drug Holidays on Hip Fracture Rates
Jeffrey R. Curtis¹, Rui Chen², Zixu (Eric) Li², Tarun Arora², Kenneth Saag³, Nicole C. Wright⁴, Shanette Daigle², Meredith Kilgore⁵ and Elizabeth Delzell⁶, ¹Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³Department of Medicine, Veterans Administration San Diego Healthcare System/UC San Diego, San Diego, CA, ⁴Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ⁵Health Care Organization & Policy, University of Alabama at Birmingham, Birmingham, AL, ⁶Retired - University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Given FDA warnings, drug holidays (temporary or permanent discontinuation) of bisphosphonates (BPs) after long-term (3-5 years) continuous therapy is becoming increasingly common in the…
Abstract Number: 829 • 2017 ACR/ARHP Annual Meeting
Unraveling Race and Social Context in Understanding Disparities in Lupus Mortality in the United States
Titilola Falasinnu¹, Yashaar Chaichian², Latha Palaniappan³ and Julia F Simard⁴, ¹Health Research and Policy, Stanford University, Stanford, CA, ²Medicine, Immunology & Rheumatology Division, Stanford School of Medicine, Stanford, CA, ³Stanford University Medical Center, General Medical Disciplines, Stanford, CA, ⁴Division of Epidemiology, Health Research and Policy Department, Stanford School of Medicine, Stanford, CA
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that is a source of significantly decreased life expectancy in the United States. Women and…
Abstract Number: 830 • 2017 ACR/ARHP Annual Meeting
Performance on Quality Measures in the RISE Registry and the Merit-Based Incentive Payment System (MIPS)
Jinoos Yazdany¹, Tracy Johansson², Rachel Myslinski³ and Salahuddin Kazi⁴, ¹Medicine/Rheumatology, University of California San Francisco, San Francisco, CA, ²Practice, Advocacy & Quality, American College of Rheumatology, Atlanta, GA, ³Governance & Ethics Specialist, Amer College of Rheumatology, Atlanta, GA, ⁴University of Texas Southwestern, Dallas, TX
Background/Purpose: Under the new Medicare Access and CHIP Reauthorization Act (MACRA), the quality of care rheumatologists provide will have financial repercussions through the Merit Based…
Abstract Number: 831 • 2017 ACR/ARHP Annual Meeting
Interferon-Alpha Disrupts Tolerance in a Mouse Model of B Cell Anergy
Dario Ferri¹, Yuriy Baglaenko², Kieran Manion², Nan-Hua Chang² and Joan E. Wither³, ¹Immunology, University of Toronto, Toronto, ON, Canada, ²Genetics and Development, Krembil Research Institute, University Health Network, Toronto, ON, Canada, ³Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Systemic Lupus Erythematosus (SLE) is characterized by the production of anti-nuclear antibodies that deposit within tissues leading to organ damage. A central mediator of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].